BTI-322 for induction therapy after renal transplantation: A randomized study

Transplantation Proceedings

Volumn 29, Issue 1-2, 1997, Pages 317-319

  Squifflet, J P ^a   Besse, T ^b   Malaise, J ^b   Mourad, M ^b   Delcorde, C ^b   Hope, J A ^b   Pirson, Y ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD2 ANTIGEN; CYCLOSPORIN A; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BTI 322; OKT 3; PREDNISOLONE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; CADAVER KIDNEY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TUMOR;

EID: 0030958080     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(96)00282-5     Document Type: Conference Paper

References (6)

1. Xia H, Ravoet AM, Latinne D, et al: In Bazin H (ed): Rat Hybridoma and Monoclonal Antibodies. Boca Raton: CRC Press, 1990, p 309
2. Latinne D. De La Parra B, Nizet Y, et al: International Immunol 8:1113, 1996
3. Schad V, Greenstein JL, Giovino-Barry V, et al: Transplant Proc 28:2051, 1996
4. Giovino-Barry V, Latinne D, Xu Y. et al: FASEB J 9:A242, 1995
5. White-Scharf ME, Hope JA, Kenty G, et al: The 9th International Congress of Immunology. Abstract Book (#5260). 1995, p 887
6. Besse T, Baldi A, Bazin H. et al: BTI-322 treatment for acute rejection after renal transplantation. Abstract. Am Soc Transplant Physicians Meeting, Dallas, TX, 1996